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INTRODUCTION
Preterm birth (PTB), delivery prior to 37 weeks’ gestation, is the leading cause of mortality among
non-anomalous neonates. Survivors carry an increased risk for lifelong intellectual, physical, and
social disabilities compared with their term counterparts (Russell et al., 2007; Bodeau-Livinec et al.,
2008; Vohr, 2013; Manuck et al., 2014a, 2016b; Natarajan and Shankaran, 2016). In the US alone,
more than 450,000 babies are born too soon and ∼25,000 die as a result (Hamilton et al., 2015).
Approximately two-thirds of all PTBs are spontaneous PTB (SPTB), and occur following preterm
premature rupture of membranes, cervical insufficiency, and/or uterine contractions leading to
cervical dilation. To reduce the burden of SPTB, interventions must target both prematurity
prevention prior to the onset of symptoms and acute treatment once the process of acute preterm
labor has begun.
Research efforts to develop treatments to improve neonatal outcomes have met some success
[e.g., 17-alpha hydroxprogesterone caproate for recurrent SPTB prevention (Meis et al., 2003),
antenatal corticosteroid treatment to prevent sequelae of prematurity (Roberts and Dalziel, 2006;
Gyamfi-Bannerman and Thom, 2016)]. However, our ability to effectively prevent and treat
SPTB remains limited. Of the available treatment options, significant inter-individual variation is
appreciated. The reasons for this response variation are poorly understood and represent a critical
knowledge gap contributing to thousands of SPTB every year. Refinement of patient selection for
available drugs, or changing the form or dose of medication has the potential for large impact on
therapeutic efficacy. Here we highlight two examples of medications currently used to reduce SPTB
and discuss how cutting edge approaches may improve outcomes (Table 1).
PREVENTION OF RECURRENT SPTB WITH INTRAMUSCULAR
PROGESTERONE
A personal history of SPTB is the strongest clinical risk factor, conferring a 2- to 4-fold risk for
SPTB (Hamilton et al., 2015). In a large multi-center randomized controlled trial conducted by
the NICHDMaternal-Fetal Medicine Units Network, Meis et al. studied weekly intramuscular 17-
alpha hydroxyprogesterone caproate (17-OHPC) vs. placebo in women with a history of a prior
SPTB. The rate of recurrent SPTB <37 weeks gestation was reduced from 55% in the placebo
group to 36% in the 17P group (RR 0.66, 95% CI 0.54–0.81; Meis et al., 2003). Currently, offering
250mg intramuscular 17-OHPC weekly from 16 to 36 weeks gestation to women with a singleton
pregnancy and a history of a prior singleton SPTB <37 weeks is standard of care in the United
States (Committee on Practice Bulletins-Obstetrics and The American College of Obstetricians and
Gynecologists, 2012; Society for Maternal-Fetal Medicine Publications Committee, with assistance
of Vincenzo Berghella, 2012). Unfortunately, 17-OHPC is only effective for some women and as
many as 30–40% will experience a recurrent SPTB despite treatment. The mechanism of action of
17-OHPC has not yet been elucidated.
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TABLE 1 | Listed is a summary of example medications for prevention and treatment of spontaneous preterm birth, along with current and future
approaches to optimize response to these therapeutic interventions.
Indication Example medication Optimizing response to therapy
Current Future
Prevention of
prematurity
17-OHPC - Predict response based
on clinical risk factors
- Determine optimal dose based and likelihood of response based on maternal
and/or fetal genotype, methylome, transcriptome
- Interrogate gene-environment interactions as etiology in variable response
- Evaluation of effects of concominant drug administration on 17-OHPC levels
Treatment of acute
preterm labor
Indomethacin - None - All of the above, plus:
- Application of nanotechnology to minimize fetal exposure while maximizing
tissue-specific effects
17-OHPC, 17-alpha hydroxyprogesterone caproate.
Assessing Reasons for Variable Response
to 17-OHPC
Several recent studies have focused on defining which individuals
are destined to have a favorable response to progesterone for
the prevention of recurrent preterm birth. These investigations
have identified several distinct and consistent clinical risk
factors for recurrent SPTB despite 17-OHPC therapy, including
black race, gonorrhea or chlamydia infection, vaginal bleeding,
family history of SPTB, male fetus (Manuck et al., 2016a,c).
Pharmacogenomic studies assessing recurrent SPTB among
women using 17-OHPC have been pre-clinical in nature, but
have also shown promising results, implicating biologically
plausible pathways including the nitric oxide pathway and
other genetic pathways involved with signal transduction and
infection and inflammation (Manuck et al., 2014b; Manuck,
2016). Unfortunately, insufficient sample numbers, difficulties in
defining adequate treatment “response” and lack of randomized
studies has prevented this work from reaching direct clinical
applicability (Manuck, 2016). Studies examining more acute
genetic changes (e.g., epigenetic modifications) in response to the
environmental stimuli of 17-OHPC are also currently limited but
may offer additional avenues of research and eventual clinical
application. Finally, it is possible that genotype or methylation
changes affect birth outcomes only in the presence of a certain
critical threshold or serum level of 17-OHPC. Many drugs taken
by women for a variety of indications during pregnancy are
metabolized by the cytochrome P450 enzyme system; 17-OHPC
is also metabolized by the cytochrome P450 system, primarily
CYP3A (Sharma et al., 2010). Interactions with co-administered
CYP3A inhibitors or inducers may influence 17-OHPC drug
metabolism and clinical efficacy (Sharma et al., 2008). No studies
examining the effects of concomitant drug administration with
17-OHPC have been published to date, though in vitro data
suggests these other CYP-metabolized drugs may impact 17-
OHPC levels (Sharma et al., 2008).
Using State-of-the-Art Genetic Technology
to Investigate Other Reasons for Variable
Outcomes
Epigenetic modifications provide a mechanism by which genes
interact with the environment; they affect gene expression by
inducing structural changes in DNA that are maintained through
cell division, respond to environmental changes including drug
exposures, yet are potentially reversible and can be targets
for disease therapy (Feinberg, 2007). DNA methylation at
cytosine-guanine dinucleotides sites, the most commonly studied
epigenetic modification in humans, guides temporal, and tissue-
specific gene expression during fetal development and tissue
differentiation. Even subtle environmental changes may induce
epigenetic changes and have effects on phenotype (Golbabapour
et al., 2011). Epigenetic biomarkers from blood have been
used in a variety of complex conditions in other fields (e.g.,
depression, addiction/smoking). Moreover, these changes are
potentially reversible and reflect dynamic interactions with the
environment. For example, studies of women with breast cancer
(Antoni et al., 2012; Bower et al., 2014; Stagl et al., 2015),
caregivers of family members with dementia (Black et al., 2013),
patients with inflammatory bowel disease (Kuo et al., 2015), and
even healthy individuals (Qu et al., 2013) have shown that the
body’s response to chronic stress may be dynamic, mediated by
glucocorticoid gene expression, and at least partly reversible at
the genomic levelwhen treated with cognitive behavioral therapy
or relaxation techniques. Therefore, study of the methylome
and transcriptome is a promising and understudied avenue of
investigation in prematurity research (Fuchikami et al., 2011;
Mikeska et al., 2012; Philibert et al., 2013). Methylation is
tissue specific; results from blood, placental, or cervical tissue,
for example typically cannot be directly compared. However,
methylation studies in blood may be a reliable correlate of
physiologic processes in other tissues (Smith et al., 2014). Limited
studies of epigenetics in obstetrics have demonstrated identifiable
differences among women delivering preterm and those with
term deliveries, but more work is needed to evaluate whether
these differences may be influenced (positively or negatively) by
medication exposure or other known risks factors for SPTB, such
as vaginal bleeding or a short cervical length.
Refining Clinical Phenotype to Improve
Preterm Birth Outcome Predictions
Unfortunately, the aforementioned pharmacogenomics
associations have been modest. Larger scale genome wide
association studies of SPTB in general (without considering
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treatment response) have also been largely disappointing. It has
been hypothesized that suboptimal clinical phenotyping is a
major contributing factor to the challenges of reproducibility that
have characterized genetic investigations of prematurity. Many
genetic studies of SPTB have limited or inconsistent phenotype
information; even those that do collect detailed information
tend to be based on relatively heterogeneous groups of women.
We recently described a phenotype classification system. This
tool uses clinical data to group women into nine distinct SPTB
phenotypes (e.g., cervical insufficiency, infection/inflammation,
decidual hemorrhage), and may provide further insight beyond
the heterogenous PTB categorization, improving upon prior
classification systems (Manuck et al., 2015).
TREATMENT OF ACUTE SPONTANEOUS
PRETERM LABOR WITH INDOMETHACIN
One of the few tocolytic medications proven to prolong
pregnancy is indomethacin, a non-steroidal anti-inflammatory
medication that inhibits prostaglandin production by
blocking the conversion of arachidonic acid to prostaglandin.
Indomethacin is metabolized by CYP2C9 and carboxy esterase
(Agúndez et al., 2009). Cells in the amnion, chorion, decidua,
and myometrium exhibit enhanced prostaglandin production
in response to cytokines interleukin-1β, interleukin-6, and
tumor necrosis factor-α, and may help initiate the parturition
cascade (Romero et al., 1989a,b; Mitchell et al., 1990). It is
therefore hypothesized that indomethacin has a direct effect in
the inhibition of the inflammatory response. Indomethacin has
been shown to be more effective than placebo in prolonging
pregnancies with threatened preterm labor by >48 h, and use for
women with acute preterm labor may permit administration of
a course of antenatal corticosteroids. Despite this, indomethacin
has not been proven to improve short- or long- term neonatal
outcomes (Niebyl et al., 1980; Panter et al., 1999; Klauser et al.,
2014).
Though somewhat effective, indomethacin is not without
potential risk to the fetus, and these risks have limited its
use. Indomethacin freely crosses the placenta and enters fetal
circulation. Premature closure of the physiologically patent
ductus arteriosus is a recognized side effect of indomethacin
and is the leading reason why tocolysis with indomethacin
is generally limited to short courses of therapy (48–72 h;
Moise, 1993). Some studies suggest that neonates exposed
to antenatal indomethacin may have an increased risk of
other adverse effects including periventricular leukomalacia and
necrotizing enterocolitis (Major et al., 1994; Amin et al., 2007),
although results have been somewhat inconsistent between
studies.(Dudley and Hardie, 1985; Macones and Robinson, 1997;
Loe et al., 2005) Despite these safety concerns, indomethacin is
one of the first line recommended tocolytics by the American
Congress of Obstetricans and Gynecologists, and short courses
of indomethacin are widely used in the US for acute tocolysis due
to its relative effectiveness compared to other agents (American
College of Obstetricans and Gynecologists’ Committee on
Practice Bulletins-Obstetrics, 2016).
Assessing Reasons for Variable Response
to Indomethacin
Determination of individuals most likely to remain pregnant
48 h after indomethacin therapy is a challenge, as placebo-
controlled tocolytic studies are limited and retrospective studies
are fraught with confounding. The diagnosis of “preterm
labor” remains imperfect, and studies have traditionally used
varying definitions to determine participant eligibility. Many
women initially diagnosed with acute preterm labor will
eventually deliver at term. We are unaware of any reported
studies of indomethacin pharmacogenetics in the setting of
pregnancy, though investigation of maternal and/or fetal
genome, epigenome, methylome may shed additional light on
variation in response in a similar fashion to pharmacogenomics
investigations of 17-OHPC as outlined above.
Application of Nanomedicine to Target
Indomethacin Delivery to Gestational
Tissues
If women who are most likely to benefit from indomethacin
treatment for acute preterm labor can be identified through
pharmacogenomic or other investigations, the issue of potential
toxicity to the fetus must be resolved in order for this therapy
to be administered optimally. Recently, nanomedicine has been
investigated as one potential way to overcome this limitation.
Nanomedicine provides a mechanism to vector drugs (e.g.,
through liposomes) preferentially to diseased or target tissues in
the body, while limiting exposure (and thus toxicity) to healthy
tissues (and in the case of pregnancy, the fetus). Specifically
engineered liposomes, encapsulated with indomethacin and with
a surface oxytocin receptor antagonist, have been designed
for this purpose, to deliver indomethacin directly to the
myometrium while limiting fetal exposure. In initial murine
studies, these liposomes successfully delivered indomethacin
to the uterus and inhibited prostaglandin production—thus
maintaining its pharmacologic effects—while reducing fetal
exposure by 7.6-fold.(Refuerzo et al., 2015) In subsequent murine
models, these specifically engineered liposomes prolonged
pregnancy by 31% and reduced the rate of PTB by 15% (Refuerzo
et al., 2016). The application of nanotechnology has great
promise as a solution to the fetal toxicity appreciated with
indomethacin, and refinement of these techniques will expand
researcher’s abilities to investigate other therapeutics for SPTB
prevention and treatment with lower concern for fetal exposure.
SUMMARY
Preterm birth is a devastating obstetric complication leading
to fetal mortality and morbidity. Despite extensive research,
there remains much to learn regarding the pathophysiological
mechanisms associated with SPTB. We understand even less
about the role that epigenetic regulation and subsequent
altered gene expression play as an etiologic factor for this
condition. Progestogens and tocolytic drugs can reduce neonatal
morbidity and mortality by preventing or halting SPTB
through poorly defined mechanisms. Additional individual
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patient characteristics, including maternal and fetal genotype
and gene-environment interactions likely influence response.
Other factors, beyond the scope of this article—such as
cytochrome P450 enzyme activity, maternal body mass index,
and other considerations that may impact volume of drug
distribution may also impact response to medications for SPTB.
Studies of all SPTB therapeutics should collect and incorporate
rigorous clinical phenotype information and biologic sample
data whenever possible, in order for further refine and integrate
clinical phenotype, genotype, and response to preventative and
therapeutic medications.
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